OBJECTIVE: To discuss current therapeutic modalities for @entity291 's @entity6132 and its prevention. DATA SOURCES AND STUDY SELECTION: The sources of data include original clinical studies carried out at Ste. Justine Hospital, as well as a systematic search of the published English and French language scientific literature restricted to @entity1 subjects using computerized searches (National Public Library of Medicine, Cochrane Database Systems Review) from 1997 to 2002. Search terms for article retrieval included food @entity566 , @entity6132 , therapy, and prevention. CONCLUSIONS: The therapy of @entity5419 depends upon an accurate diagnosis, which remains a challenge in non--IgE-mediated cases. Dietary exclusion remains the mainstay of therapy, with medications reserved for exceptional @entity1 . Preliminary evidence suggests that pancreatic enzyme supplementation may be of benefit for cases with multiple @entity5419 and severe @entity484 . Hydrolysate formula use is currently recommended for dietary @entity566 prevention in @entity1 at an increased risk when maternal milk is insufficient or unavailable. The use of partially hydrolyzed formulas to prevent @entity56 , including @entity483 , is supported by clinical studies, but cannot be used in the already sensitized, milk-allergic @entity1 . Probiotics show enormous potential in preventing @entity56 as well.

Therapeutic modalities for @entity291 's XXXX .

@entity1 :: ('9606', 'Species') :: ['human', 'patients', 'infants', 'child'] @entity483 :: ('MESH:D003876', 'Disease') :: ['atopic dermatitis'] @entity5419 :: ('MESH:D005512', 'Disease') :: ['food allergies'] @entity6132 :: ('MESH:D016269', 'Disease') :: ['milk allergy'] @entity566 :: ('MESH:D006967', 'Disease') :: ['allergy'] @entity56 :: ('MESH:D004342', 'Disease') :: ['allergic disorders', 'food allergic disorders'] @entity291 :: ('9913', 'Species') :: ['cow'] @entity484 :: ('MESH:D004485', 'Disease') :: ['eczema']
@entity6132 :: (MESH:D016269,Disease) :: ['milk allergy']
